Welcome to the Hawaii Chapter of the American College of Cardiology


2026 Conference
Click here to learn about our annual Chapter meeting April 25, 2026
Click here to download the flyer

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings


RSS Latest in Cardiology from ACC.org

  • Third-Trimester Pregnancy Biomarkers Associated With Greater CV Risk
    Higher concentrations in the third trimester of the pregnancy-specific biomarker soluble fms-like tyrosine kinase-1 (sFlt-1) and the cardiovascular-specific biomarker high-sensitivity cardiac troponin I (hs-cTnI) were both independently associated with subsequent cardiovascular disease, according to research published Feb. 18 in JAMA Cardiology, suggesting that pregnancy may be a unique and important opportunity for cardiovascular risk assessment.
  • ACC CardiaCast: 2025 ACC Concise Clinical Guidance on Evaluation and Management of ATTR-CM
    In this podcast, Drs. Michelle Kittleson and Jan Griffin provide a practical overview of evaluation and management of transthyretin amyloid cardiomyopathy (ATTR-CM) based on ACC’s 2025 Concise Clinical Guidance document the Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.
  • REVELUTION: More Coronary Plaque Progression With Leuprolide Than Relugolix in Prostate Cancer
    In men with localized prostate cancer (PCa) treated with radiation and androgen-deprivation therapy (ADT), treatment with the gonadotropin-releasing hormone (GnRH) leuprolide was associated with a significant 12-month increase in coronary artery plaque volume when compared with treatment with relugolix, according to a brief report of the REVELUTION trial published Feb. 18 in JAMA.
  • 20-Year Outcomes For PVI in Patients With Drug-Refractory Paroxysmal AFib
    Twenty years after pulmonary vein isolation (PVI) during catheter ablation, stable sinus rhythm was maintained in a quarter of patients with symptomatic drug-refractory paroxysmal atrial fibrillation (PAF), including those taking antiarrhythmic drugs and those who had multiple ablation procedures, according to findings from a study published Feb. 17 in JACC: Clinical Electrophysiology.
  • Medtronic Clinician Update on New Evolut Valve Data Reinforces Need For Patient Dialogue
    Medtronic has issued a letter and developed web resources providing an update on long-term reintervention rates associated with its Evolut R and Evolut PRO transcatheter heart valves, drawing on complete six-year and partial seven-year follow-up data from the Evolut Low-Risk Trial published on Feb. 16 in JACC.